• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Enteris BioPharma touts more Phase II data for oral endometriosis therapy

June 26, 2018 By Sarah Faulkner

Enteris BiopharmaEnteris BioPharma this week touted positive results from the final treatment arm of a Phase IIa trial of Ovarest, the company’s oral formulation of leuprolide.

The drug is designed as an alternative to the injectable therapies available for people with endometriosis.

Data from the last treatment arm of Enteris’ Phase IIa trial showed that the optimized Ovarest formulation and dose triggered estradiol suppression in healthy volunteers at levels that were in line with Lupron Depot, an injectable formulation of leuprolide.

Based on the positive data from its Phase IIa trial, Enteris reported that it plans to advance Ovarest into Phase IIb development.

“The objective of the last Phase IIa treatment arm was to demonstrate that an optimized tablet formulation at a 10 mg twice-daily dose would further improve estradiol suppression. We are very pleased to report that the data hit the mark, showing that Ovarest tablets are now expected to demonstrate similar efficacy to Lupron Depot and other products developed and being developed to treat endometriosis,” executive chairman & CEO Joel Tune said in prepared remarks. “It is Enteris’ strategy to partner Ovarest and all its internal pipeline products either at the proof-of-concept stage or before they enter Phase III.”

Enteris’ ‘Peptellingence’ platform is designed to overcome the challenges of oral peptide delivery. A person’s gastrointestinal tract degrades and digests peptides and a normal peptide can’t break through the intestinal cell layer to be absorbed.

To tackle this problem, Enteris has developed a coating that stops the peptide from opening in the stomach. Instead, the therapy dissolves only once it reaches the small intestine.

The company also uses a compound to boost the intestinal cell layer’s permeability, temporarily widening the gaps between cells to facilitate drug transfer, Tune explained in an interview last year with Drug Delivery Business News.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Women's Health Tagged With: enterisbiopharma

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS